NCT06697301
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06697301
Title Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eikon Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SWE | POL | NZL | NOR | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS


No variant requirements are available.